Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Glycans as Master Switches of B Cell Activity in Autoimmunity

Project description

The role of glycosylation in autoimmune diseases

Glycosylation is a post-translational modification process that involves the addition of sugar molecules to proteins. In the immune system, glycosylation plays an essential role in regulating the interactions between immune cells and their environment. In the case of antibodies, glycosylation at the fragment antigen-binding (Fab) region affects the antigen-binding affinity of antibodies and may lead to the development and progression of autoimmune diseases. The ERC-funded GlycanSwitch project aims to investigate the cellular mechanisms underlying Fab glycosylation and its effects on the immune system. Researchers will focus on the glycosylation of the B cell receptor and its role in the selection and activation of autoreactive B cells. Project findings will provide the groundwork for targeted therapies against autoimmunity.

Objective

Autoimmune diseases including rheumatoid arthritis (RA) are often life-threatening disorders with increasing disability having a negative impact on patients’ quality of life. Mechanisms leading to the breach of tolerance in development of autoimmunity are still largely unknown. Protein glycosylation is an essential regulatory mechanism in the immune system. We recently demonstrated that N-glycosylation of the variable region (Fab) of autoantibodies is a hallmark of RA development and progression. We also demonstrated that autoantibodies acquire these Fab glycosylation signatures already many years before disease onset. We herein hypothesize that Fab glycosylation at the level of the B cell receptor is a key molecular switch promoting the selection, activation and proliferation of autoreactive B cells leading to the concomitant breach of immunotolerance. Within GlycanSwitch, we will map the Fab glycome of various types of RA autoantibodies and autoreactive B cells. We will study the factors and underlying cellular mechanisms that regulate Fab glycosylation of B cell receptors and autoantibodies. We will investigate the immunological effects of Fab glycosylation and the impact in B cells signalling and activation in the context of molecular and cellular interacting partners in the immune microenvironment. Finally, we will test in relevant mouse models how Fab glycosylation of autoantibodies and autoreactive B cells contributes to the breach of tolerance. We expect that the obtained insights into the role of glycans as key checkpoint for the selection of autoreactive B cells and the rise of autoimmunity will provide leads for targeted therapeutic interventions as well as rationales for the early detection of RA and autoimmune diseases in general. We foresee that the knowledge generated will allow us to embark on a targeted prevention clinical study in patients at risk for RA to turn off the GlycanSwitch leading to chronic RA.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-SYG - HORIZON ERC Synergy Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-SYG

See all projects funded under this call

Host institution

ACADEMISCH ZIEKENHUIS LEIDEN
Net EU contribution
€ 5 000 000,00
Address
ALBINUSDREEF 2
2333 ZA Leiden
Netherlands
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 5 000 000,00

Beneficiaries (4)